news
Direct anticoagulants associated with increased risk of bleeding
Results of a study suggest the need for caution in the prescription of direct oral anticoagulants for patients with chronic kidney disease, due to the risk of bleeding...
List view / Grid view
Warfarin
Filter the results
news
New anti-clotting drugs linked to lower risk of serious bleeding
Direct oral anticoagulants (DOACs) used to treat serious blood clots are associated with reduced risks of major bleeding compared with the older anti-clotting drug, warfarin, finds a new study.
news
Anticoagulant drugs appear to reduce the risk of stroke in patients with AF
Blood-thinning drugs not only reduce the risk of stroke in patients with AF but are also associated with a significant reduction in the risk of dementia...
news
DOACs used as a alternative to warfarin to treat venous thromboembolism
A study has found that a new group of drugs used to treat patients with serious blood clots are not associated with a higher risk of major bleeding compared with warfarin...
news
Dual antithrombotic therapy cuts bleeding risk
Researchers have found that using just two anti-clotting medicines for atrial fibrillation is safer than using the current standard treatments...
news
Phase 3 data show Daiichi Sankyo’s once-daily edoxaban lowered incidence of VTE recurrence and clinically relevant bleeding
10 December 2013 | By Daiichi Sankyo Company
This analysis of VTE patients with cancer was presented at the 2013 American Society of Hematology Annual Meeting and Exposition...
news
Daiichi Sankyo’s once-daily edoxaban meets primary efficacy endpoint for stroke prevention and superiority for the principal safety endpoint compared to Warfarin for patients with atrial fibrillation in a phase 3 clinical trial
20 November 2013 | By Daiichi Sankyo Europe
Once-daily edoxaban, evaluated in two treatment arms achieved the primary endpoint of non-inferior efficacy versus warfarin in the prevention of stroke or systemic embolism...
news
Better outcome in case of major bleed for patients taking the anticoagulant Pradaxa® compared to warfarin
Anticoagulants are an indispensable treatment to prevent dangerous blood clots that can cause devastating ischaemic strokes in patients with atrial fibrillation or life-threatening pulmonary embolism in patients with venous thromboembolism.1,2 An increased risk of bleeding is a known possible complication of all anticoagulant therapies.3 This research shows that applying existing…
news
Daiichi Sankyo’s once-daily edoxaban shows comparable efficacy and superiority for the principal safety endpoint compared to warfarin in a Phase 3 study for the treatment of symptomatic VTE and prevention of its recurrence
1 September 2013 | By Daiichi Sankyo
Daiichi Sankyo announced results from the global phase 3 Hokusai-VTE study...
news
Treatment with Pradaxa® associated with better patient outcomes after a major bleeding event compared to warfarin
10 December 2012 | By Boehringer Ingelheim
Results from a new post-hoc analysis...
news
AF patients who require surgery benefit from a shorter treatment interruption on dabigatran etexilate (Pradaxa®) compared to warfarin
18 June 2012 | By Boehringer Ingelheim
Pradaxa® is associated with a substantially shorter interruption of oral anticoagulation therapy...
news
FDA affirms superiority of Pradaxa® (dabigatran etexilate) 150mg over warfarin in reduction of both ischaemic and haemorrhagic strokes
6 June 2012 | By Boehringer Ingelheim
Boehringer Ingelheim has updated the US prescribing information for Pradaxa®...
news
ELIQUIS® (apixaban) superior to Warfarin for the reduction of stroke or systemic embolism
28 August 2011 | By Bristol-Myers Squibb Company, Pfizer
Significantly less major bleeding in patients with Atrial Fibrillation in Phase 3 ARISTOTLE trial...